Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance.
about
Antiretroviral therapy response among HIV-2 infected patients: a systematic reviewThe K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaborationGenotypic resistance profiles of HIV-2-treated patients in West Africa.HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimensAntiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsCharacteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study.Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors.Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cellsThe Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.Novel inhibitors of human immunodeficiency virus type 2 infectivity.Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.Fidelity of classwide-resistant HIV-2 reverse transcriptase and differential contribution of K65R to the accuracy of HIV-1 and HIV-2 reverse transcriptases.Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance
P2860
Q27003854-0A2C2CFE-472A-45D8-B7FE-ED511ED4533BQ33681279-4F5A54CB-94DB-44BC-ABF0-9410C0EC1FDCQ33891896-953502E5-D3A7-4026-8FF2-FD3FC297B0EBQ33954546-6101F272-5D6A-400A-9B12-5AED3C1431D0Q33963958-C4CD4A5B-1C25-4E0A-8A4B-5A8FFD6CD3A2Q34428902-0EC914F2-5D5F-4D6D-978B-EF382986DFE5Q34730950-48515312-F4B2-4C4E-9E7A-1CD244BA03ACQ34793224-B31B0B4A-6EAE-4B1D-A36B-A9C312020BC2Q34992731-8A37E477-50AA-4C5A-AC66-45303501B589Q35134947-550FB778-03C5-46FC-A49D-EA222F9E04B3Q35943486-9D1DDCBD-F406-4E6B-8F99-F6768609922BQ36202747-808F9652-6689-46EF-88B9-F5338DAC7DE7Q36290647-61656085-A838-45C4-AA3F-A501E6A00274Q36839676-6D99DEE4-9286-4439-A00E-231D8DE82027Q37026564-AEBFE878-25BB-468F-AF75-5160D741B15BQ37517645-AFAA385F-C6F9-4C67-9309-85C13AB8EBE4Q37859395-E26FCC13-6BFD-40B6-9739-C241BDBCDE04Q38755690-0C141A43-CD8C-4DC3-A1C3-315184097351Q38820118-ECDBA722-4B87-4659-AD44-A8FF7648DC0FQ38967949-39477989-B81E-4EF7-BEB5-E11AEF17DCF4Q40249141-993E431B-7076-44D6-B161-BBB79F1BCC9AQ40278530-D512C4BC-8A1D-4F4B-A35D-BEAD1E3A7006Q44990505-8251FC6C-1542-4FD9-844F-CE51368CBE74Q47560712-9990F0EE-DAF8-42B2-84AA-B1BE398592CAQ58391480-CC695F90-C131-405D-B896-B8313240A26C
P2860
Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Antiretroviral drug resistance ...... ucleoside analogue resistance.
@en
Antiretroviral drug resistance ...... ucleoside analogue resistance.
@nl
type
label
Antiretroviral drug resistance ...... ucleoside analogue resistance.
@en
Antiretroviral drug resistance ...... ucleoside analogue resistance.
@nl
prefLabel
Antiretroviral drug resistance ...... ucleoside analogue resistance.
@en
Antiretroviral drug resistance ...... ucleoside analogue resistance.
@nl
P2093
P2860
P356
P1476
Antiretroviral drug resistance ...... ucleoside analogue resistance.
@en
P2093
Bradley D Preston
Crystal L Pyrak
Donovan J Anderson
Geoffrey S Gottlieb
Robert A Smith
P2860
P304
P356
10.1086/597802
P407
P577
2009-05-01T00:00:00Z